NCT01411228View on ClinicalTrials.gov

A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

August 31, 2014

Conditions
Gaucher Disease
Interventions
DRUG

Taliglucerase alfa

Taliglucerase alfa for infusion every two weeks for 24 months

Trial Locations (3)

Unknown

Shaare Zedek Medical Center, Jerusalem

Instituto Privado de Hematologia E Investigacion Clinica (I.P.H.I.C), Barrio Asunción

Morningside Medi-Clinic, Morningside

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY